Close Menu

NEW YORK – Researchers at the Medical University of Warsaw in Poland have developed a biomarker that they said could be the basis for a noninvasive test to assess intestinal function.

Intestinal diseases such as inflammatory bowel disease (IBD) are characterized by an impairment of the gut-blood barrier (GBB), colloquially known as "leaky gut." Leaky gut is an increased permeability of the intestinal walls that can allow bacteria and their products to pass from the gut into the bloodstream, sometimes triggering inflammation or an immune response.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.